Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges: 2018-2025

Historic Amortization of Deferred Charges for Tg Therapeutics (TGTX) over the last 7 years, with Sep 2025 value amounting to $304,000.

  • Tg Therapeutics' Amortization of Deferred Charges fell 26.57% to $304,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 47.88%. This contributed to the annual value of $2.0 million for FY2024, which is 16.11% down from last year.
  • As of Q3 2025, Tg Therapeutics' Amortization of Deferred Charges stood at $304,000, which was down 0.00% from $304,000 recorded in Q2 2025.
  • Tg Therapeutics' 5-year Amortization of Deferred Charges high stood at $639,000 for Q2 2023, and its period low was $231,000 during Q1 2021.
  • In the last 3 years, Tg Therapeutics' Amortization of Deferred Charges had a median value of $461,000 in 2023 and averaged $480,455.
  • As far as peak fluctuations go, Tg Therapeutics' Amortization of Deferred Charges spiked by 99.57% in 2022, and later tumbled by 52.58% in 2024.
  • Over the past 5 years, Tg Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $386,000 in 2021, then increased by 19.43% to $461,000 in 2022, then soared by 38.61% to $639,000 in 2023, then plummeted by 52.58% to $303,000 in 2024, then fell by 26.57% to $304,000 in 2025.
  • Its Amortization of Deferred Charges stands at $304,000 for Q3 2025, versus $304,000 for Q2 2025 and $304,000 for Q1 2025.